E
AIM ImmunoTech Inc. AIM
$0.12 -$0.0034-2.76%
Recommendation
Sell
Prev Close
$0.1234
Volume
665,897
Avg Vol (90D)
910,403
Market Cap
$7.87M
Dividend & Yield
--
52-Week Range
$0.1105 - $0.62
P/E (TTM)
--
EPS (TTM)
-$0.4761
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
AIM ImmunoTech Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference
3/11/2025 - Globe Newswire
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
2/28/2025 - Globe Newswire
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
2/26/2025 - Globe Newswire
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
2/26/2025 - Globe Newswire
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
2/25/2025 - Globe Newswire
AIM ImmunoTech Releases Virtual Investor What This Means Segment
2/11/2025 - Globe Newswire
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
2/11/2025 - Globe Newswire
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen and AstraZeneca's FluMist to address the recent avian influenza outbreaks
2/7/2025 - Globe Newswire
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
2/5/2025 - Globe Newswire
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
1/23/2025 - Globe Newswire
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
1/22/2025 - Globe Newswire
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
1/15/2025 - Globe Newswire
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
12/17/2024 - Globe Newswire
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
12/12/2024 - Globe Newswire
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
12/6/2024 - Globe Newswire
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
11/19/2024 - Globe Newswire
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/15/2024 - Globe Newswire
AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
11/6/2024 - Globe Newswire
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
10/9/2024 - Globe Newswire
AIM ImmunoTech Granted U.S. Patent for Ampligen for the Treatment of Endometriosis
10/3/2024 - Globe Newswire
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
9/30/2024 - Globe Newswire
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
9/27/2024 - Globe Newswire
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
9/19/2024 - Globe Newswire
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential to Improve the Post-COVID Condition of Fatigue
9/11/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$190.00K
EBITDA (TTM)
-$27.68M
EBIT (TTM)
-$27.92M
Net Income (TTM)
-$23.93M
Balance Sheet
Total Assets (Q)
$13.59M
Total Debt (Q)
$3.40M
Total Liabilities (Q)
$10.68M
Book Value Per Share (Q)
$0.0496
Cash Flow
Cash from Operations (TTM)
-$20.69M
Cash from Investing (TTM)
$788.00K
Cash from Financing (TTM)
$5.55M
Net Change in Cash (TTM)
-$14.35M
Filings
Filing Date
Thursday, November 14, 2024
Period Date
Monday, September 30, 2024
Next Filing
Beginning of April (est)
Price History
Loading...
Beta
0.45
7-Day Total Return
-2.76%
30-Day Total Return
-39.76%
60-Day Total Return
-43.66%
90-Day Total Return
-52.57%
Year to Date Total Return
-44.70%
1-Year Total Return
-66.67%
2-Year Total Return
-74.19%
3-Year Total Return
-84.42%
5-Year Total Return
-95.79%
52-week Low
Feb 25, 2025 - $0.1105
52-week High
Apr 11, 2024 - $0.62
Valuation
Market Cap
$7.87M - Nano Cap
Enterprise Value
$4.07M
Price/Sales (TTM)
38.56
Price/Book (Q)
2.49
Dividends and Shares
Shares Outstanding
57.68M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
aimimmuno.com
Phone Number
352 448 7797
Address
2117 SW Highway 484
Ocala, FL 34473
Country
United States
Year Founded
1966
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the... more
AMEX 03/13/2025 4:00PM Eastern Quotes delayed
Weiss Ratings